02:02 PM EDT, 07/22/2025 (MT Newswires) -- Liminatus Pharma ( LIMN ) initiated a review to evaluate including regulated digital assets as part of its broader treasury management.

The core focus remains on advancing cancer therapies, the company said Tuesday in a statement.

"This is an exploratory process only" with no agreements set on the acquisition or use of digital assets, the company said.

Liminatus shares rose 8.5% in recent Tuesday trading.

Price: 6.05, Change: +0.47, Percent Change: +8.51